Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia

被引:136
|
作者
Esposito, Susanna [1 ]
Tagliabue, Claudia [1 ]
Picciolli, Irene [1 ]
Semino, Margherita [1 ]
Sabatini, Caterina [1 ]
Consolo, Silvia [1 ]
Bosis, Samantha [1 ]
Pinzani, Raffaella [1 ]
Principi, Nicola [1 ]
机构
[1] Univ Milan, Dept Maternal & Pediat Sci, Fdn IRCCS Ca Granda, Osped Maggiore Policlin, I-20122 Milan, Italy
关键词
Antibiotic therapy; Antibiotics; Children; Community-acquired pneumonia; Pediatrics; Procalcitonin; RESPIRATORY-TRACT INFECTIONS; C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED PNEUMONIA; ERYTHROCYTE SEDIMENTATION-RATE; SERUM PROCALCITONIN; PNEUMOCOCCAL PNEUMONIA; BACTERIAL PNEUMONIA; CHILDREN; INTERLEUKIN-6; MULTICENTER;
D O I
10.1016/j.rmed.2011.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to evaluate the use of an algorithm based on a procalcitonin (PCT) cut-off value as a means of guiding antibiotic therapy, 319 hospitalised children with uncomplicated community-acquired pneumonia (CAP) were randomised 1:1 to be treated on the basis of the algorithm or in accordance with standard guidelines. The children in the PCT group did not receive antibiotics if their PCT level upon admission was <0.25 ng/mL, and those receiving antibiotics from the time of admission were treated until their PCT level was >0.25 ng/mL. The final analysis was based on 155 patients in the PCT group and 155 in the control group. In comparison with the controls, the PCT group received significantly fewer antibiotic prescriptions (85.8% vs 100%; p < 0.05), were exposed to antibiotics for a shorter time (5.37 vs 10.96 days; p < 0.05), and experienced fewer antibiotic-related adverse events (3.9% vs 25.2%; p < 0.05), regardless of CAP severity. There was no significant between-group difference in recurrence of respiratory symptoms and new antibiotic prescription in the month following enrollment. The results of this first prospective study using a PCT cut-off value to guide antibiotic therapy for pediatric CAP showed that this approach can significantly reduce antibiotic use and antibiotic-related adverse events in children with uncomplicated disease. However, because the study included mainly children with mild to moderate CAP and the risk of the use of the algorithm-based approach was not validated in a relevant number of severe cases, further studies are needed before it can be used in routine clinical practice. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1939 / 1945
页数:7
相关论文
共 50 条
  • [1] Procalcitonin for Diagnostics and treatment Decisions in Pediatric Lower respiratory tract infections
    Baumann, Philipp
    Baer, Gurli
    Bonhoeffer, Jessica
    Fuchs, Aline
    Gotta, Verena
    Heininger, Ulrich
    Ritz, Nicole
    Szinnai, Gabor
    Bonhoeffer, Jan
    FRONTIERS IN PEDIATRICS, 2017, 5
  • [2] Lung ultrasound and procalcitonin, improving antibiotic management and avoiding radiation exposure in pediatric critical patients with bacterial pneumonia: a randomized clinical trial
    Guitart, Carmina
    Bobillo-Perez, Sara
    Rodriguez-Fanjul, Javier
    Carrasco, Jose Luis
    Brotons, Pedro
    Lopez-Ramos, Maria Goretti
    Cambra, Francisco Jose
    Balaguer, Monica
    Jordan, Iolanda
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01)
  • [3] Procalcitonin and community-acquired pneumonia (CAP) in children
    Giulia, Bivona
    Luisa, Agnello
    Concetta, Scazzone
    Bruna, Lo Sasso
    Chiara, Bellia
    Marcello, Ciaccio
    CLINICA CHIMICA ACTA, 2015, 451 : 215 - 218
  • [4] Procalcitonin for Antibiotic Treatment in Intensive Care Unit Patients
    Layios, Nathalie
    Lambermont, Bernard
    CURRENT INFECTIOUS DISEASE REPORTS, 2013, 15 (05) : 394 - 399
  • [5] Emerging problems in the treatment of pediatric community-acquired pneumonia
    Principi, Nicola
    Esposito, Susanna
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2018, 12 (07) : 595 - 603
  • [6] Procalcitonin for guidance of antibiotic therapy
    Schuetz, Philipp
    Albrich, Werner
    Christ-Crain, Mirjam
    Chastre, Jean
    Mueller, Beat
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2010, 8 (05) : 575 - 587
  • [7] Procalcitonin-Guided Antibiotic Discontinuation Might Shorten the Duration of Antibiotic Treatment Without Increasing Pneumonia Recurrence
    Akagi, Takanori
    Nagata, Nobuhiko
    Wakamatsu, Kentaro
    Harada, Taishi
    Miyazaki, Hiroyuki
    Takeda, Satoshi
    Ushijima, Shinichiro
    Aoyama, Takashi
    Yoshida, Yuji
    Yatsugi, Hiroshi
    Wada, Kenji
    Ueda, Yusuke
    Fujita, Masaki
    Watanabe, Kentaro
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2019, 358 (01) : 33 - 44
  • [8] The Use of the Biomarker Procalcitonin in Pediatric Cardiovascular Disorders
    Sahulee, Raj
    McKinstry, Jaclyn
    Chakravarti, Sujata B.
    CURRENT PEDIATRICS REPORTS, 2019, 7 (03) : 63 - 69
  • [9] Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy
    Creamer, Andrew W.
    Kent, Alice E.
    Albur, Maha
    BREATHE, 2019, 15 (04) : 296 - 304
  • [10] Role of procalcitonin in guiding antibiotic therapy
    Fazili, Tasaduq
    Endy, Timothy
    Javaid, Waleed
    Maskey, Mitu
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (23) : 2057 - 2061